Intermediatebiotechnology
Sickle Cell Disease Genetics
Overview
Sickle cell disease: a single base change (GAG->GTG) in HBB (chromosome 11) substitutes valine for glutamate at beta-globin position 6; deoxygenated HbS polymerizes, sickling red cells and blocking vessels. Autosomal recessive for anemia (codominant at the protein level). Heterozygote advantage against malaria maintains the allele (balanced polymorphism). Casgevy (CRISPR) now offers cure.
Learning objectives
- Explain the Glu6Val molecular mechanism
- Describe sickling pathophysiology
- Explain heterozygote advantage
- Describe modern treatments including CRISPR
One base, one amino acid
HBB codon 6: GAG (glutamate, hydrophilic surface) -> GTG (valine, hydrophobic). Deoxygenated HbS exposes the valine patch; complementary pockets on adjacent tetramers bind: fibers form, cells sickle. Pauling 1949: the first 'molecular disease.'
A surface sticky spot, exposed only when deoxygenated: the elegant horror of HbS.
From sickle to crisis
Sickled cells are rigid and adhesive: vaso-occlusive pain crises, acute chest syndrome, stroke, splenic infarction (infection risk), hemolytic anemia. Homozygotes (HbSS) severely affected; HbSC and HbS/beta-thalassemia compound heterozygotes vary.
Exertion, altitude, dehydration, infection: anything lowering oxygen promotes sickling.
Balanced polymorphism
Heterozygotes (HbAS, sickle trait) resist severe malaria: HbS impairs Plasmodium growth. Where malaria kills, the allele persists despite homozygote cost: the textbook heterozygote advantage (Allison, 1954). Trait carriers are mostly asymptomatic (rare exertional risk).
Sickle, thalassemia, G6PD: malaria shaped the human genome more than any other pathogen.
Treatment and cure
Hydroxyurea (raises HbF), transfusions, penicillin prophylaxis, stem-cell transplant (curative, donor-limited). 2023: Casgevy (CRISPR editing BCL11A to reactivate fetal hemoglobin) and Lyfgenia approved: genetic cures. Gene therapy access and cost are the new barriers.
Fetal hemoglobin doesn't polymerize: reactivating it bypasses the mutation entirely.
Key points
- GAG->GTG (Glu6Val): hydrophobic patch polymerizes deoxygenated HbS
- Vaso-occlusion causes pain crises, chest syndrome, stroke
- HbAS heterozygotes resist malaria: balanced polymorphism
- Hydroxyurea, transplant; CRISPR Casgevy reactivates HbF
Common misconceptions
✓ Truth: Trait (HbAS) is essentially benign; disease needs two sickle-pathway alleles.
✓ Truth: Only deoxygenated HbS polymerizes: oxygenation reverses it; crises need triggers.
Practice questions
Q1. Sickle cell anemia is caused by
- GAG->GTG (Glu6Val) in HBB
- A deletion
- Trisomy
- Methylation
The classic missense: glutamate to valine at beta-6.
Q2. The sickle allele persists because heterozygotes
- Are smarter
- Resist severe malaria
- Live longer always
- Have more children always
Balanced polymorphism: malaria protection vs homozygote disease.
Q3. Casgevy treats sickle cell by
- Transfusion
- CRISPR reactivation of fetal hemoglobin
- Antibiotics
- Splenectomy
Editing BCL11A restores HbF, which blocks polymerization.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why does HbF help?
Gamma-globin lacks the valine patch and dilutes HbS: mixed tetramers can't polymerize efficiently.
What is acute chest syndrome?
Sickling/infection in lungs: the leading cause of death, a medical emergency.
How common is sickle cell?
~100,000 Americans, millions in sub-Saharan Africa: a global health burden, not a rare disease.